Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Receivables (2020 - 2025)

Biofrontera (BFRI) has 6 years of Receivables data on record, last reported at $3.0 million in Q3 2025.

  • For Q3 2025, Receivables fell 38.55% year-over-year to $3.0 million; the TTM value through Sep 2025 reached $3.0 million, down 38.55%, while the annual FY2024 figure was $5.3 million, 33.25% down from the prior year.
  • Receivables reached $3.0 million in Q3 2025 per BFRI's latest filing, down from $4.0 million in the prior quarter.
  • Across five years, Receivables topped out at $13.9 million in Q1 2022 and bottomed at $2.1 million in Q3 2021.
  • Average Receivables over 5 years is $6.2 million, with a median of $5.3 million recorded in 2024.
  • Peak YoY movement for Receivables: skyrocketed 277.96% in 2021, then crashed 53.08% in 2024.
  • A 5-year view of Receivables shows it stood at $12.4 million in 2021, then fell by 17.56% to $10.2 million in 2022, then decreased by 22.31% to $8.0 million in 2023, then tumbled by 33.25% to $5.3 million in 2024, then crashed by 43.65% to $3.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $3.0 million in Q3 2025, $4.0 million in Q2 2025, and $4.2 million in Q1 2025.